February 10th, 2023
•Here, we describe a protocol in which an acute lymphoblastic leukemia patient-derived xenograft model is used as a strategy to assess and monitor CD19-targeted chimeric antigen receptor T cell-associated toxicities.
Tags
Related Videos
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Assessment of the Metabolic Profile of Primary Leukemia Cells
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
A Melanoma Patient-Derived Xenograft Model
Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved